PAVmed Investor Relations Material
Latest events
Q2 2024
PAVmed
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from PAVmed Inc
Access all reports
PAVmed Inc. holds interests in various medical device technologies at various stages of development. Its initial pipeline includes: carPIX, a technology that transforms the humble stethoscope into a highly effective imaging tool; EsoGuard/EsoCheck, a novel, multi-marker screening test for esophageal cancer and Barrett's esophagus; PortIO, an implantable intraosseous vascular access device that could revolutionize the way patients needing vascular access are treated.
NextCath, a revolutionary self-anchoring catheter technology based on an internally developed platform that eliminates the need for sutures or tissue adhesives to secure a catheter to the body; and NextVessel, which is being developed by NextCath Inc., and is designed to provide early detection of coronary atherosclerosis and other vascular conditions. PAVmed Inc. was founded in 2014 and is headquartered in New York, New York.
Latest articles
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Ticker symbol
PAVM
Country
🇺🇸 United States